1. Medicaid Spending on Antiretrovirals From 2007 Through 2019.
- Author
-
Walsh BS, Kesselheim AS, and Rome BN
- Subjects
- United States, Humans, Drug Costs, Drugs, Generic therapeutic use, Anti-Retroviral Agents therapeutic use, Medicaid, HIV Infections drug therapy
- Abstract
Background: Antiretroviral (ARV) medications to treat human immunodeficiency virus (HIV) are a major contributor to Medicaid prescription drug spending. Despite having been used for over 3 decades, the first generic ARVs only recently became available, and many newer versions continue to be sold at high prices despite within-class competition. We estimated Medicaid spending on ARVs from 2007 through 2019., Methods: Using public Medicaid State Drug Utilization data, we identified trends in ARV spending and use from 2007 through 2019. We estimated net spending and average prices (spending per 30-day supply), accounting for statutory Medicaid rebates, including a 15%-23% base rebate plus additional rebates if a drug's price increased faster than inflation., Results: Among 48 ARVs, estimated net Medicaid spending from 2007 through 2019 was $25 billion for 17 million 30-day supplies. Annual use increased 118%, from 0.7 million 30-day supplies in 2007 to 1.6 million in 2019. During this time, estimated annual net spending increased 178%, from $1.1 billion to $3.0 billion, and average net prices increased 28%, from $1432 to $1830 per 30-day supply., Conclusions: Annual Medicaid net spending on ARVs nearly tripled from 2007 to 2019, due to a combination of expanded use and rising prices. Medicaid did not extract expected benefits from its mandatory inflationary rebates because they were offset by use of newer, more expensive ARVs. To better control spending related to products with incremental innovation, the US government should be authorized to assure that launch prices for new drugs are aligned with the added benefit they offer over existing therapies., Competing Interests: Potential conflicts of interest. This work was conducted and submitted while B. S. W. was a fellow with the Program On Regulation, Therapeutics, And Law (PORTAL). He has since completed the fellowship and now works as an associate at Hogan Lovells US LLP. A. S. K. reports serving as an expert witness on behalf of a class of plaintiffs in a lawsuit against Gilead related to FDA approval of its tenofovir-containing products. B. N. R. reports grants or contracts from Anthem Public Policy Institute (grant to Brigham and Woman's Hospital). The authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF